Halozyme Therap Drug Patent Portfolio

Halozyme Therap's Family Patents


Family Patents



Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Halozyme Therap News

Two Lesser-Known Biotech Companies Poised for Growth in 2026 - The Globe and Mail

25 Jan, 2026

Halozyme and Quinn Emanuel win preliminary injunction against MSD regarding Keytruda SC - JUVE Patent

08 Dec, 2025

Halozyme secures German court order halting the distribution of Merck's Keytruda.

08 Dec, 2025

Merck faces a challenge with its new Keytruda formulation in Germany - STAT News

05 Dec, 2025

See More